Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG001 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT05155839Phase 1Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRG001 in B-cell non-Hodgkin lymphoma, sponsored by Hangzhou Miracogen. Primary endpoints: Adverse Events (AEs), Maximum Tolerated Dose and 1 more. Status: unknown.
02
Drugs
MRG001
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05155839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155839.